Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; ...
FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an ...
Selecta Biosciences is jumping into Cartesian’s cell therapy cockpit, preparing to take flight once again after landing nearly all of its previous programs. The two companies announced a reverse ...
Cell therapy developer Cartesian Therapeutics (NASDAQ:RNAC) announced Tuesday that its lead asset, Descartes-08, reached the main goal in a mid-stage trial against the muscle disorder myasthenia ...
The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...
Zacks Investment Research on MSN
Cartesian Therapeutics, Inc. (RNAC) upgraded to buy: What does it mean for the stock?
Investors might want to bet on Cartesian Therapeutics, Inc. (RNAC), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results